Ebola virus disease

BMJ (Online)

Volumn 349, Issue , 2014, Pages

  Beeching, Nicholas J ^a   Fenech, Manuel ^a   Houlihan, Catherine F ^b  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DERIVATIVE; AMIODARONE; ANTACID AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AVI 6002; AVI 7537; BCX 4430; BENZODIAZEPINE DERIVATIVE; BRINCIDOFOVIR; CHLOROQUINE; CLOMIFENE; EBOLA VACCINE; FAVIPIRAVIR; MONOCLONAL ANTIBODY; NARCOTIC ANALGESIC AGENT; PARACETAMOL; PROTON PUMP INHIBITOR; RNA POLYMERASE; RNA POLYMERASE L; SEDATIVE AGENT; SMALL INTERFERING RNA; TKM EBOLA; UNCLASSIFIED DRUG; ZMAPP; ANTIVIRUS AGENT;

ABDOMINAL PAIN; ADENOVIRUS INFECTION; AGITATION; BLEEDING; BODY FLUID; CONTACT EXAMINATION; CONVALESCENCE; CYTOMEGALOVIRUS INFECTION; DEHYDRATION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DYSPHAGIA; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; ENDEMIC DISEASE; FATALITY; FEVER; FILOVIRUS INFECTION; HEADACHE; HEALTH CARE PERSONNEL; HEARTBURN; HEPATOMEGALY; HICCUP; HUMAN; HYPOVOLEMIA; INCUBATION TIME; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA; INTENSIVE CARE; LOSS OF APPETITE; LYMPHADENOPATHY; MACULOPAPULAR RASH; MALARIA; MYALGIA; NAUSEA; NONHUMAN; PAIN; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PROGNOSIS; PROTECTIVE EQUIPMENT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEIZURE; SEPSIS; SEPTIC SHOCK; TRAVEL; UPPER ABDOMINAL PAIN; VIRUS GENOME; VIRUS LOAD; VIRUS TRANSMISSION; VOMITING; ZOONOSIS; AFRICA; DISEASE OUTBREAKS; EARLY DIAGNOSIS; EPIDEMIOLOGY; FLUID THERAPY; HEMORRHAGIC FEVER, EBOLA; ORGANIZATION AND MANAGEMENT; PROCEDURES; PROTECTIVE CLOTHING; RISK ASSESSMENT; TRANSMISSION;

AFRICA, WESTERN; ANTIVIRAL AGENTS; COMMUNICABLE DISEASE CONTROL; DIAGNOSIS, DIFFERENTIAL; DISEASE OUTBREAKS; EARLY DIAGNOSIS; EBOLA VACCINES; FLUID THERAPY; HEMORRHAGIC FEVER, EBOLA; HUMANS; PHYSICAL EXAMINATION; PROGNOSIS; PROTECTIVE CLOTHING; RISK ASSESSMENT;

EID: 84915819223     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g7348     Document Type: Review

References (84)

1. Centers for Disease Control and Prevention. About Ebola virus disease. 2014. www.cdc.gov/.
2. WHO. Are the Ebola outbreaks in Nigeria and Senegal over? 2014. www.who.int/.
3. WHO Ebola Response Team. Ebola virus disease in West Africa: the first 9 months of the epidemic and forward projections. N Engl J Med 2014;371:1481-95.
4. Centers for Disease Control and Prevention. Ebola fact sheet. 2014. www.cdc.gov/.
5. Bah EI, Lamah MC, Fletcher T, Jacob ST, Brett-Major DM, Sall AA, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med 2014; published online 5 Nov. doi:10.1056/NEJMoa1411249.
6. Hensley LE, Wahl-Jensen V, McCormick JB, Rubins KH. Viral hemorrhagic fevers. In: Cohen J, Powderly W, Opal S, eds. Infectious diseases. 3rd ed. Mosby; 2010:1231-7.
7. Peters CJ, LeDuc JW. An introduction to Ebola: the virus and the disease. J Infect Dis 1999;179(suppl 1):9-16.
8. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011;377:849-62.
9. Swanepoel R, Smit SB, Rollin PE, Formenty P, Leman PA, Kemp A, et al. Studies of reservoir hosts for Marburg virus. Emerg Infect Dis 2007;13:1847-51.
10. Peterson AT, Bauer JT, Mills JN. Ecologic and geographic distribution of filovirus disease. Emerg Infect Dis 2004;10:40-7.
11. Swanepoel R, Leman PA, Burt FJ, Zachariades NA, Braack LE, Ksiazek TG, et al. Experimental inoculation of plants and animals with Ebola virus. Emerg Infect Dis 1996;2:321-5.
12. Reiter P, Turell M, Coleman R, Miller B, Maupin G, Liz J, et al. Field investigations of an outbreak of Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: arthropod studies. J Infect Dis 1999;179(suppl 1):S148-54.
13. Dowell SF, Mukunu R, Ksiazek TG, Khan AS, Rollin PE, Peters CJ. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit. J Infect Dis 1999;179(suppl 1):S87-91.
14. Report of an International Commission. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 1978;56:271-93.
15. Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya M, Sanchez A, et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 2007;196(suppl 2):S142-7.
16. Emond RT, Evans B, Bowen ET, Lloyd G. A case of Ebola virus infection. BMJ 1977;2:541-4.
17. Rowe AK, Bertolli J, Khan AS, Mukunu R, Muyembe-Tamfum JJ, Bressler D, et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémies à Kikwit. J Infect Dis 1999;179(suppl 1):S28-35.
18. Kreuels B, Wichmann D, Emmerich P, Schmidt-Chanasit J, de Heer G, Kluge S, et al. A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med 2014; published online 22 Oct.
19. Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 2004;4:487-98.
20. Beeching NJ, Fletcher TE, Hill DR, Thomson GL. Travellers and viral haemorrhagic fevers: what are the risks? Int J Antimicrob Agents 2010;36(suppl 1):S26-35.
21. Ramanan P, Shabman RS, Brown CS, Amarasinghe GK, Basler CF, Leung DW. Filoviral immune evasion mechanisms. Viruses 2011;3:1634-49.
22. Ramanan P, Edwards MR, Shabman RS, Leung DW, Endlich-Frazier AC, Borek DM, et al. Structural basis for Marburg virus VP35-mediated immune evasion mechanisms. Proc Natl Acad Sci U S A 2012;109:20661-6.
23. Fletcher T, Fowler RA, Beeching NJ. Understanding organ dysfunction in Ebola virus disease. Intensive Care Med 2014;40:1936-9.
24. Sanchez A, Lukwiya M, Bausch D, Mahanty S, Sanchez AJ, Wagoner KD, et al. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol 2004;78:10370-7.
25. Zapata JC, Cox D, Salvato MS. The role of platelets in the pathogenesis of viral hemorrhagic fevers. PLoS Negl Trop Dis 2014;8:e2858.
26. Leroy EM, Baize S, Volchkov VE, Fisher-Hoch SP, Georges-Courbot MC, Lansoud-Soukate J, et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 2000;355:2210-5.
27. WHO. Case definition for Ebola or Marburg virus disease. 2014. www.who.int/.
28. Fletcher TE, Brooks TJ, Beeching NJ. Ebola and other viral haemorrhagic fevers. BMJ 2014;349:g5079.
29. Centers for Disease Control and Prevention. Guidance on personal protective equipment to be used by healthcare workers during management of patients with Ebola virus disease in U.S. hospitals, including procedures for putting on (donning) and removing (doffing). 2014. www.cdc.gov/.
30. Centers for Disease Control and Prevention. Interim guidance for monitoring and movement of persons with Ebola virus disease exposure. 2014. www.cdc.gov/.
31. WHO. Clinical management of patients with viral haemorrhagic fever: a pocket guide for the front-line health worker. 2014. http://apps.who.int/.
32. Public Health England. Marburg virus disease: origins, reservoirs, transmission and guidelines. 2014. www.gov.uk.
33. Public Health England. Crimean-Congo haemorrhagic fever: origins, reservoirs, transmission and guidelines. 2014. www.gov.uk.
34. Public Health England. Lassa fever: origins, reservoirs, transmission and guidelines. 2014. www.gov.uk.
35. Hartskeerl RA, Collares-Pereira M, Ellis WA. Emergence, control and re-emerging leptospirosis: dynamics of infection in the changing world. Clin Microbiol Infect 2011;17:494-501.
36. Mendelson M, Han PV, Vincent P, von Sonnenburg F, Cramer JP, Loutan L, et al. Regional variation in travel-related illness acquired in Africa, March 1997-May 2011. Emerg Infect Dis 2014;20:532-41.
37. Centers for Disease Control and Prevention. Case definition for Ebola virus disease (EVD). 2014. www.cdc.gov/.
38. Chertow DS, Kleine C, Edwards JK, Scaini R, Giuliani R, Sprecher A. Ebola virus disease in West Africa - clinical manifestations and management. N Engl J Med 2014;371:2054-7.
39. Dananché C, BénetT, Vanhems P. Ebola: fever definitions might delay detection in non-epidemic areas. Lancet 2014;384:1743.
40. Mupere E, Kaducu OF, Yoti Z. Ebola haemorrhagic fever among hospitalised children and adolescents in northern Uganda: epidemiologic and clinical observations. Afr Health Sci 2001;1:60-5.
41. Peacock G, Uyeki TM, Rasmussen SA. Ebola virus disease and children: what pediatric health care professionals need to know. JAMA Pediatr 2014; published online 17 Oct.
42. Public Health England. Ebola virus disease: clinical management and guidance. 2014. www.gov.uk/government/collections/ebola-virus-disease-clinical-management-and-guidance
43. Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis 2011;204(suppl 3):S810-6.
44. Bwaka MA, Bonnet MJ, Calain P, Colebunders R, De Roo A, Guimard Y, et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis 1999;179(suppl 1):S1-7.
45. Formenty P, Hatz C, Le Guenno B, Stoll A, Rogenmoser P, Widmer A. Human infection due to Ebola virus, subtype Côte d'Ivoire: clinical and biologic presentation. J Infect Dis 1999;179(suppl 1):S48-53.
46. Roddy P, Howard N, Van Kerkhove MD, Lutwama J, Wamala J, Yoti Z, et al. Clinical manifestations and case management of Ebola haemorrhagic fever caused by a newly identified virus strain, Bundibugyo, Uganda, 2007-2008. PLoS One 2012;7:e52986.
47. Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK, Colubri A, et al; KGH Lassa Fever Program; Viral Hemorrhagic Fever Consortium; WHO Clinical Response Team. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med 2014;371:2092-100.
48. WHO. Laboratory guidance for the diagnosis of Ebola virus disease: interim recommendations. 2014. www.who.int/.
49. Towner JS, Rollin PE, Bausch DG, Sanchez A, Crary SM, Vincent M, et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol 2004;78:4330-41.
50. Rollin PE, Bausch DG, Sanchez A. Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis 2007;196(suppl 2):S364-71.
51. McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Nichol ST, Towner JS, et al. Biomarker correlates of survival in pediatric patients with ebola virus disease. Emerg Infect Dis 2014;20:1683-90.
52. Fowler RA, Fletcher T, Fischer WA 2nd, Lamontagne F, Jacob S, Brett-Major D, et al. Caring for critically ill patients with Ebola virus disease. Perspectives from West Africa. Am J Respir Crit Care Med 2014;190:733-7.
53. Auffermann WF, Kraft CS, Vanairsdale S, Lyon GM 3rd, Tridandapani S. Radiographic imaging for patients with contagious infectious diseases: how to acquire chest radiographs of patients infected with the Ebola virus. AJR Am J Roentgenol 2014; published online 17 Nov.
54. Parra JM, Salmerón OJ, Velasco M. The first case of Ebola virus disease acquired outside Africa. N Engl J Med 2014; published online 19 Nov.
55. Lyon GM, Mehta AK, Varkey JB, Brantly K, Plyler L, McElroy AK, et al; the Emory Serious Communicable Diseases Unit. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 2014 published online 12 Nov. doi:10.1056/NEJMoa1409838.
56. Decker BK, Sevransky JE, Barrett K, Davey RT, Chertow DS. Preparing for critical care services to patients with Ebola. Ann Intern Med 2014; published online 23 Sep.
57. Canadian Critical Care Society, Canadian Association of Emergency Physicians, Association of Medical Microbiology and Infectious Diseases of Canada. Ebola clinical care guidelines: guide for clinicians in Canada. 2014. http://cccsnew.businesscatalyst.com/.
58. European Centre for Disease Prevention and Control. Epidemiological update: outbreak of Ebola virus disease in West Africa. 2014. www.ecdc.europa.eu.
59. Connor MJ Jr, Kraft C, Mehta AK, Varkey JB, Lyon GM, Crozier I, et al. Successful delivery of RRT in Ebola virus disease. J Am Soc Nephrol 2014; published online 14 Nov.
60. Wada H, Thachil J, Di Nisio M, Mathew P, Kurosawa S, Gando S, et al. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost 2013; published online 4 Feb.
61. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580-637.
62. Bishop BM. Potential and emerging treatment options for Ebola virus disease. Ann Pharmacother 2014; published online 20 Nov.
63. WHO. Potential Ebola therapies and vaccines. 2014. http://www.who.int/csr/resources/publications/ebola/potential-therapies-vaccines/en/.
64. Gulland A. Clinical trials of Ebola therapies to begin in December. BMJ 2014;349:g6827.
65. Zhang Y, Li D, Jin X, Huang Z. Fighting Ebola with ZMapp: spotlight on plant-made antibody. Sci China Life Sci 2014;57:987-8.
66. Goodman JL. Studying "secret serums": toward safe, effective Ebola treatments. N Engl J Med 2014;371:1086-9.
67. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014;514:47-53.
68. McCarthy M. US signs contract with ZMapp maker to accelerate development of the Ebola drug. BMJ 2014;349:g5488.
69. Thi EP, Mire CE, Ursic-Bedoya R, Geisbert JB, Lee AC, Agans KN, et al. Marburg virus infection in nonhuman primates: therapeutic treatment by lipid-encapsulated siRNA. Sci Transl Med 2014;6:250ra116.
70. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010;375:1896-905.
71. Choi JH, Croyle MA. Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs 2013;27:565-83.
72. Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, et al. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 2009;82:95-102.
73. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 2014;508:402-5.
74. Iversen PL, Warren TK, Wells JB, Garza NL, Mourich DV, Welch LS, et al. Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections. Viruses 2012;4:2806-30.
75. Turone F. Doctors trial amiodarone for Ebola in Sierra Leone. BMJ 2014;349:g7198.
76. Ledgerwood JE, DeZure AD, Stanley DA, Novik L, Enama ME, Berkowitz NM, et al; the VRC 207 Study Team. Chimpanzee adenovirus vector Ebola vaccine - preliminary report. N Engl J Med 2014; published online 26 Nov. doi:10.1056/NEJMoa1410863.
77. Sadek RF, Khan AS, Stevens G, Peters CJ, Ksiazek TG. Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival. J Infect Dis 1999;179(suppl 1):S24-7.
78. Mupapa K, Mukundu W, Bwaka MA, Kipasa M, De Roo A, Kuvula K, et al. Ebola hemorrhagic fever and pregnancy. J Infect Dis 1999;179(suppl 1):S11-2.
79. Jamieson DJ, Uyeki TM, Callaghan WM, Meaney-Delman D, Rasmussen SA. What obstetrician-gynecologists should know about Ebola: a perspective from the Centers for Disease Control and Prevention. Obstet Gynecol 2014; published online 8 Sep.
80. Association of Women's Health, Obstetric and Neonatal Nurses. Ebola: caring for pregnant and postpartum women and newborns in the United States: AWHONN practice brief number 3. J Obstet Gynecol Neonat Nurs 2014; published online 24 Nov. doi:10.1111/1552-6909.12518.
81. Leroy EM, Gonzalez JP, Baize S. Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. Clin Microbiol Infect 2011;17:964-76.
82. McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Nichol ST, Towner JS, et al. Ebola hemorrhagic fever: novel biomarker correlates of clinical outcome. J Infect Dis 2014;210:558-66.
83. De Roo A, Ado B, Rose B, Guimard Y, Fonck K, Colebunders R. Survey among survivors of the 1995 Ebola epidemic in Kikwit, Democratic Republic of Congo: their feelings and experiences. Trop Med Int Health 1998;3:883-5.
84. Locsin RC, Barnard A, Matua AG, Bongomin B. Surviving Ebola: understanding experience through artistic expression. Int Nurs Rev 2003;50:156-66.